Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem in Healthy Elderly Volunteers

Next Previous
Trial Profile

XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem in Healthy Elderly Volunteers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emestedastat (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms XanaMIA-DR
  • Sponsors Actinogen Medical

Most Recent Events

  • 20 Jul 2023 Results assessing the effects of Xanamem on cognition from XanaHES (n= 42, 20 mg) and XanaMIA (n=105, 5 & 10 mg) and XanADu-X biomarker extension study (n=72, 10 mg), presented at the Alzheimer's Association International Conference 2023.
  • 06 Apr 2022 Status changed from active, no longer recruiting to completed.
  • 06 Dec 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top